drugset / Trial / NCT00424892

Study Evaluating DVS SR in Patients With Fibromyalgia Syndrome

NCT00424892

Phase 2/3 Completed 600 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The primary objective is to evaluate the long-term safety of desvenlafaxine succinate sustained-release (DVS SR) during open-label treatment in adult outpatients with fibromyalgia syndrome.

Timeline

Start
Primary completion
Completion
2007-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Desvenlafaxine Other / unclassified

Indications